Detailed contribution information
| Contribution title | 2701 - New augmentation strategy in treatment of hyperkinetic conduct disorder (pilot study) |
|---|---|
| Contribution code | PS02-45 (P) |
| Authors | |
| Form of presentation | Poster |
| Topic |
|
| Abstract |
Objectives. In 35–65% of ADHD patients conduct problems are also part of the clinical picture. Children with ADHD and conduct disorder co-occurrence tend to have more severe ADHD symptoms, greater functional impairment, poorer quality of life. However whether comorbid conduct problems represent a separate disorder or a severe ADHD form remains controversial. Hyperkinetic conduct disorder (HCD) is a mixed category in ICD-10 that combines ADHD and conduct disorder symptoms, assuming that it is an undivided clinical entity. In practice caring for these patients is associated with considerable difficulties. Pharmacotherapy often does not reduce the symptoms completely and children’s social functioning and quality of life are increased insufficiently. Studying the effects of a broader range of treatments is required to find ways of improving treatment outcome, and Hopantenic acid (neuroprotective drug approved in Russia for ADHD treatment but with vague evidence base) augmentation may be beneficial. Aim: evaluate the efficacy of Hopantenic acid augmentation in HCD treatment for children with insufficient efficiency of previous atomoxetine therapy. Methods. 24 children (16 boys, 8 girls) aged 6 - 12 years with HCD (ICD-10) with insufficient response to atomoxetine for 3 previous months were enrolled in the open study. They received age-appropriate doses of Hopantenic acid during one month. CGI, CGAS, CHIP-CE were used at baseline, after 1 month of Hopantenic acid therapy, after 2 months. Results. Improvements in clinical assessment (decrease in hyperactivity, increase in attention) and social functioning of children with HCD, evident after the first month of Hopantenic acid augmentation, tended to strengthen at the final assessment. Noticeable improvements were observed in levels of social functioning measured by CGAS. According to CHIP-CE pronounced improvements were recorded in Achievement Domain (Academic Performance), Resilience Domain (Family Involvement), Comfort Domain (Emotional Comfort). No serious side effects were noted. Conclusion. The findings of this pilot open study suggest: HCD in some cases may be considered as a single target entity and Hopantenic acid augmentation may be beneficial resulting in improved treatment outcome and social functioning of these children. It remains uncertain whether Hopantenic acid exerts a specific and enduring effect on conduct symptoms. Further studies are required to replicate findings. |